Telix Pharmaceuticals Limited (ASX: TLX) has entered into an exclusive commercial distribution agreement with Madrid-based NUCLIBER S.A. Spain (NUCLIBER) for Telix’s prostate cancer investigational imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11 injection) for the Spanish market.
Under the terms of the agreement, and subject to closing requirements being satisfied, NUCLIBER will be the overall distributor and local representative for Illuccix in Spain, an EU5 country, from the national approval date. NUCLIBER has demonstrated experience in the supply of gallium generators across Spain and has been selected according to its ability to deliver a secure and continuous supply of 68Ga necessary for commercial launch in the country.
NUCLIBER is a leading nuclear medicine company in Spain, and we are therefore pleased to have entered into this commercial distribution agreement as we prepare for the European launch of Illuccix,” Telix EMEA President, Richard Valeix, said.
Collaborating with such an established and patient- centric leader in radiopharmaceuticals will help Telix to deliver on the promise of nuclear medicine with the ultimate aim to improve outcomes for Spanish men living with prostate cancer.”
About Prostate Cancer in Spain
In 2020, prostate cancer was the most commonly diagnosed cancer in men in Spain, with approximately 34,600 new cases being diagnosed, exhibiting a significantly higher incidence in men than either lung cancer (21,500 new cases) or bowel cancer (24,600 new cases). Prostate cancer was also a leading cause of cancer death in men, with almost 5,800 men dying from the disease in Spain in 2020. Almost 137,000 Spanish men were estimated to be living with prostate cancer in 2020.4
About NUCLIBER
NUCLIBER was founded in 1962 as a company designing and manufacturing equipment for various applications in industry using ionizing radiation. NUCLIBER pioneered the supply of radioisotopes in Spain in the industrial, medical and research fields.
Today NUCLIBER is focused on nuclear medicine, oncology, and non-destructive testing, offering a wide range of products. NUCLIBER was founded with a vocation for service and quality.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead product, Illuccix (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA),5 and accepted for filing by the U.S. FDA.6 Telix is also progressing marketing authorisation applications for Illuccix in the European Union7 and Canada.8
With the exception of Illuccix in Australia, none of Telix’s products have received a marketing authorisation in any jurisdiction. In Brazil, Illuccix has been granted exceptional authorisation.9
